Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Adult
Antigens, CD19
/ immunology
Disease-Free Survival
Female
Hematopoietic Stem Cell Transplantation
Humans
Immunotherapy, Adoptive
/ methods
Lymphocyte Depletion
Male
Middle Aged
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
/ mortality
Receptors, Chimeric Antigen
Remission Induction
/ methods
Salvage Therapy
/ methods
Young Adult
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
11 04 2019
11 04 2019
Historique:
received:
07
11
2018
accepted:
28
01
2019
pubmed:
8
2
2019
medline:
18
12
2019
entrez:
8
2
2019
Statut:
ppublish
Résumé
Autologous T cells engineered to express a CD19-specific chimeric antigen receptor (CAR) have produced impressive minimal residual disease-negative (MRD-negative) complete remission (CR) rates in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, the factors associated with durable remissions after CAR T-cell therapy have not been fully elucidated. We studied patients with relapsed/refractory B-ALL enrolled in a phase 1/2 clinical trial evaluating lymphodepletion chemotherapy followed by CD19 CAR T-cell therapy at our institution. Forty-five (85%) of 53 patients who received CD19 CAR T-cell therapy and were evaluable for response achieved MRD-negative CR by high-resolution flow cytometry. With a median follow-up of 30.9 months, event-free survival (EFS) and overall survival (OS) were significantly better in the patients who achieved MRD-negative CR compared with those who did not (median EFS, 7.6 vs 0.8 months;
Identifiants
pubmed: 30728140
pii: S0006-4971(20)42636-9
doi: 10.1182/blood-2018-11-883710
pmc: PMC6460418
doi:
Substances chimiques
Antigens, CD19
0
Receptors, Chimeric Antigen
0
Banques de données
ClinicalTrials.gov
['NCT01865617']
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1652-1663Subventions
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK056465
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA136551
Pays : United States
Organisme : NIH HHS
ID : S10 OD020069
Pays : United States
Organisme : NIDDK NIH HHS
ID : U54 DK106829
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 by The American Society of Hematology.
Références
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
Nat Rev Drug Discov. 2017 Sep 29;16(10):669
pubmed: 28959944
Leukemia. 2016 Feb;30(2):492-500
pubmed: 26369987
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Blood. 2017 Nov 23;130(21):2295-2306
pubmed: 28924019
Blood. 2012 Sep 6;120(10):2032-41
pubmed: 22493293
Blood. 1985 Oct;66(4):778-82
pubmed: 3862434
PLoS One. 2018 Sep 24;13(9):e0203965
pubmed: 30248111
Cancer Discov. 2017 Dec;7(12):1404-1419
pubmed: 29025771
Mol Ther. 2018 Apr 4;26(4):976-985
pubmed: 29503204
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
Biol Blood Marrow Transplant. 2003 Jul;9(7):472-81
pubmed: 12869961
Blood. 1980 Sep;56(3):351-5
pubmed: 6931618
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Cancer Res. 1963 Jan;23:112-7
pubmed: 14015495
Blood. 2007 Feb 1;109(3):944-50
pubmed: 17032921
Cancer Biomark. 2017 Jul 4;19(4):353-363
pubmed: 28582845
Arch Pathol Lab Med. 2006 May;130(5):680-90
pubmed: 16683886
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Blood. 2011 Aug 4;118(5):1255-63
pubmed: 21653320
Blood. 2017 Jun 22;129(25):3322-3331
pubmed: 28408462
Blood. 2010 Jul 22;116(3):366-74
pubmed: 20404137
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Lancet. 2015 Feb 7;385(9967):517-528
pubmed: 25319501
J Clin Oncol. 2004 Jul 15;22(14):2816-25
pubmed: 15254049
Leukemia. 2007 Sep;21(9):1907-14
pubmed: 17611565
J Clin Invest. 2016 Jun 1;126(6):2123-38
pubmed: 27111235
Cancer. 2008 Dec 1;113(11):3186-91
pubmed: 18846563
Nat Med. 2018 Jan;24(1):20-28
pubmed: 29155426
Hematology Am Soc Hematol Educ Program. 2008;:381-9
pubmed: 19074114
Cancer Cell. 2015 Oct 12;28(4):415-428
pubmed: 26461090
Cancer. 1999 Oct 1;86(7):1216-30
pubmed: 10506707
Cancer Treat Rev. 2004 Feb;30(1):37-51
pubmed: 14766125
Blood. 2016 May 19;127(20):2406-10
pubmed: 26907630
Clin Exp Immunol. 1991 Nov;86(2):240-5
pubmed: 1934592
Oncotarget. 2018 May 4;9(34):23620-23627
pubmed: 29805761